6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation (Q79364253)
Jump to navigation
Jump to search
scientific article published on 01 December 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation |
scientific article published on 01 December 2003 |
Statements
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group (English)
Thomas Büchner
Wolfgang Hiddemann
Wolfgang E Berdel
Bernhard Wörmann
Claudia Schoch
Christa Fonatsch
Helmut Löffler
Torsten Haferlach
Wolf-Dieter Ludwig
Georg Maschmeyer
Peter Staib
Carlo Aul
Andreas Gruneisen
Eva Lengfelder
Norbert Frickhofen
Wolfgang Kern
Hubert L Serve
Rolf M Mesters
Maria Cristina Sauerland
Achim Heinecke
German AML Cooperative Group
1 December 2003